Compare Docusign Inc (DOCU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Recursion Pharmaceuticals Inc — how do they compare? Docusign Inc trades at $71.13 (market cap $13.35B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Docusign Inc is far larger — about 6.2× Recursion Pharmaceuticals Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DOCU | RXRX | |
|---|---|---|
Market Cap | $13.35B | $2.14B |
Volume | 3,158,858 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $73.14 | $6.79 |
52-Week Low | $41.75 | $2.84 |
Typical Hold Time | 71 Days | 23 Days |
Enterprise Value | $12.76B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.08, up 3.16% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is solid, and profitability metrics like net income margin and ROE show significant improvement. Recent news highlights AI integration in contract processing and leadership in workflow software, though insider selling has been noted.
The outlook for DOCU is positive, driven by earnings beats and AI adoption, but risks include valuation concerns with a P/E of 43.55 and insider selling. The consensus price target of $68.75 suggests limited upside from current levels, indicating a cautious stance from analysts despite bullish technical signals.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
